Emergency Approval To Vaccines Covovax & Corbevax and Anti-viral drug Molnupiravir

Approval to Vaccines Covovax and Corbevax and Anti-viral drug Molnupiravir: A Subject Expert Committee (SEC) under India's drug regulator has granted Emergency Use Authorisation (EUA) to Serum Institute of India's Covovax, Biological E's Corbevax and antiviral Covid-19 pill molnupiravir. This is being considered a significant move in combating the virus.

Central Drugs Standard Control Organisation (CDSCO) which falls under the Ministry of Health and Family Welfare has given emergency use authorisation approval to COVID19 vaccines Covovax & Corbevax and Anti-viral drug Molnupiravir, says Health Minister Dr Mansukh Mandaviya, the ANI reported. The recommendations have been sent to the Drug Controller General of India (DCGI) they will soon decide on approval. As per reports, the two new vaccines may be used as booster shots in the coming days.

The drug Molnupiravir has been approved for restricted emergency use. It can be used for the treatment of adult patients with SpO2 93 per cent and also in case of high risk of progression of the disease, including hospitalisation or death, subject to certain conditions.

The US Food and Drug Administration recently authorised Molnupiravir for the treatment of mild-to-moderate COVID-19 cases in adults in the high-risk category. In November, Britain granted conditional authorisation to coronavirus antiviral as well. It is known as

The pill is intended to be taken twice a day for five days by people at home with mild to moderate Covid-19. In a clinical trial of high-risk people during the early course of illness, the Merck’s drug was shown to reduce hospitalisations and deaths by around 30 per cent.

The US Food and Drug Administration recently authorised Merck’s Molnupiravir for treatment of mild-to-moderate COVID-19 cases in adults who are at risk for severe disease. Before that in November Britain granted conditional authorisation to the coronavirus antiviral. It is known as Merck’s Molnupiravir.

Suggested Reading: 

Here’s How Children In The 15-18 years Age Group Can Register For Covid-19 Vaccines

The SEC said, “The committee noted that the vaccine is manufactured by technology transfer from Novavax and is approved by the European Medicines Agency for conditional marketing authorisation and also granted emergency use listing by WHO.”

Biological E’s Corbevax vaccine has also got authorisation for restricted emergency use in adults. The final decision now lies with the DCGI.